In July 2021, FDA approved the first interchangeable biosimilar insulin product (Semglee–Viatris/Biocon Biologics, insulin glargineyfgn), which can be substituted for its reference product (Lantus–Sanofi Aventis, insulin glargine) at the pharmacy level, depending on state pharmacy laws.